Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Director | July 07, 2025 | July 10, 2025 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director · Chief Executive Officer | February 07, 2024 | February 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date July 07, 2025 · Filed July 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 308,846 |
Reported balance
After 2025-07-07 transaction · row 1
1 source rowRow 1 · 2025-07-07 · Sale · Disposed 10,000 · Balance 308,846 F1: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $18.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $18.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Kyverna Therapeutics, Inc.
Report date February 07, 2024 · Filed February 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,220 |
Reported balance
Holding disclosure · report date 2024-02-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 58,220 |
| Common StockSEC Table I · non-derivative | IndirectBy The Maag Family Irrevocable Trust | 349,321 |
Reported balance
Holding disclosure · report date 2024-02-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 349,321 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2033-11-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2033-07-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2032-11-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F3: 25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F2: 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3: 25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Miromatrix Medical Inc.
Report date December 12, 2023 · Filed December 13, 2023
Section 16 reporting ended · disclosed 2023-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,368 |
Reported balance
After 2023-12-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-12 · Other · Disposed 62,092 · Balance 58,368 F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-12-13 · Disposition to issuer · Disposed 58,368 · Balance 0 F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR").
F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company.
F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock.
F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2025 Filed Jul 10, 2025 20:04 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 10,000 | $18.58 | $185,831.00 |
DisclosureSEC source: 0001415889-25-019632 · form4-07102025_080700.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,846 F1 · shares: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $18.86 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:30 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 10,000 | $19.24 | $192,420.00 |
DisclosureSEC source: 0000950170-25-088541 · ownership.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 318,846 F1 · shares: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.80 to $19.52, inclusive. The reporting person undertakes to provide to CareDx, Inc., any security holder of CareDx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:31 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 12,103 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087417 · ownership.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,846 F1 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on the earlier of (i) June 13, 2026 or (ii) the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:49 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 13,281 | $17.23 | $228,795.77 |
DisclosureSEC source: 0000950170-25-062877 · ownership.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,743 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.8500 to $17.6900, inclusive. The reporting person undertakes to provide to CareDx, Inc., any security holder of CareDx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| November 26, 2024 Filed Dec 4, 2024 01:54 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0000950170-24-133034 · ownership.xml · derivative · entry 3 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 5,000 shares Expires 2028-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024. F2 · derivative.exercise_date: The shares subject to this option vested fully on June 1, 2022. Read SEC document |
| November 26, 2024 Filed Dec 4, 2024 01:54 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 5,000 | $25.00 | $125,000.00 |
DisclosureSEC source: 0000950170-24-133034 · ownership.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,024 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024. Read SEC document |
| November 26, 2024 Filed Dec 4, 2024 01:54 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 5,000 | $12.24 | $61,200.00 |
DisclosureSEC source: 0000950170-24-133034 · ownership.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 335,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 21, 2024. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:43 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 26,708 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0000950170-24-099887 · ownership.xml · derivative · entry 5 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,428 Underlying: Common Stock · 26,708 shares Expires 2033-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was originally granted on June 16, 2023 and, as of June 16, 2024, was fully vested. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:43 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 12,818 | $32.67 | $418,764.06 |
DisclosureSEC source: 0000950170-24-099887 · ownership.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,024 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.345 to $33.000, inclusive. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:43 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 13,890 | $33.25 | $461,842.50 |
DisclosureSEC source: 0000950170-24-099887 · ownership.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,842 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.75, inclusive. The reporting person undertakes to provide to CareDx, Inc., any security holder of CareDx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:43 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 8,844 | $33.23 | $293,886.12 |
DisclosureSEC source: 0000950170-24-099887 · ownership.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,732 Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:43 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 26,708 | $7.96 | $212,595.68 |
DisclosureSEC source: 0000950170-24-099887 · ownership.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 20:38 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,034 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-082720 · ownership.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,868 F1 · shares: Represents an automatic quarterly grant of common stock to the Reporting Person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:44 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 16,048 | $0.00 Strike: $9.35 | $0.00 |
DisclosureSEC source: 0000950170-24-074954 · ownership.xml · derivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,048 Underlying: Common Stock · 16,048 shares Expires 2034-06-14 F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:44 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 10,570 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074954 · ownership.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,834 F1 · shares: The reported securities are represented by restricted stock units which shall vest in one installment on June 14, 2025. Read SEC document |
| June 14, 2024 Filed Jun 20, 2024 20:43 UTC Amendment | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 16,048 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0000950170-24-075653 · ownership.xml · derivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,048 Underlying: Common Stock · 16,048 shares Expires 2034-06-14 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price of the derivative security of the Stock Option (right to buy) reported on the original Form 4. F2 · derivative.exercise_date: 1/12th of the shares subject to this option shall vest on July 14, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter through June 14, 2025. Read SEC document |
| April 29, 2024 Filed May 1, 2024 20:38 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,281 | $5.27 Strike: $5.27 | $69,990.87 |
DisclosureSEC source: 0000950170-24-051337 · ownership.xml · derivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,281 shares Expires 2026-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was originally granted on January 22, 2016 and, as of January 22, 2020, was fully vested. Read SEC document |
| April 29, 2024 Filed May 1, 2024 20:38 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 13,281 | $5.27 | $69,990.87 |
DisclosureSEC source: 0000950170-24-051337 · ownership.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:10 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,249 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042682 · ownership.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,983 F1 · shares: Represents an automatic quarterly grant of common stock to the Reporting Person in lieu of cash for non-employee director compensation pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 23:02 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-24-000010 · wk-form4_1704495764.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,734 F1 · shares: Represents an automatic quarterly grant of common stock to the Reporting Person in lieu of cash for non-employee director compensation pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| December 13, 2023 Filed Dec 13, 2023 16:50 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | Disposition to issuerCommon Stock | 58,368 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-016385 · form4-12132023_091244.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · security: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. F4 · price: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 16:50 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | OtherCommon Stock | 62,092 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-016385 · form4-12132023_091244.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,368 F1 · shares: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F1 · price: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F2 · price: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. Read SEC document |
| October 04, 2023 Filed Oct 4, 2023 23:43 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000211 · wk-form4_1696463005.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,209 F1 · shares: Represents an automatic quarterly grant of common stock to the Reporting Person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| July 13, 2023 Filed Jul 14, 2023 00:56 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 5,000 | $10.34 | $51,680.50 |
DisclosureSEC source: 0001217234-23-000159 · wf-form4_168929617681857.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,657 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.71, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 22:33 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000148 · wf-form4_168876917399582.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,657 F1 · shares: Represents an automatic quarterly grant of common stock to the Reporting Person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 00:43 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 2,432 | $8.72 | $21,215.55 |
DisclosureSEC source: 0001217234-23-000139 · wf-form4_168799942413856.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,136 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.47 to $8.87, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 22:52 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock · Derivative | 29,136 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001217234-23-000129 · wf-form4_168738791025310.xml · derivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,136 Underlying: Common Stock · 29,136 shares Expires 2033-06-16 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 16, 2023 and the shares subject to the option shall vest monthly thereafter through June 16, 2024. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 22:52 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 18,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000129 · wf-form4_168738791025310.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,568 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 16, 2024. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 16:21 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | GrantCommon Stock | 54,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009213 · form4-06052023_080654.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,460 F1 · shares: The RSUs shall vest upon the earlier of (i) the next annual meeting of the stockholders of the Company or (ii) June 1, 2024. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 21:39 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000061 · wf-form4_168142194334362.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,724 F1 · shares: Represents an automatic quarterly grant of common stock to the Reporting Person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. F2 · balance_after: The Reporting Person no longer has a reportable beneficial interest in an aggregate of 2,000 shares of the Issuer's common stock held as UTMA custodian for minor children included in the Reporting Person's prior ownership reports as such children are no longer minors. Read SEC document |
| March 10, 2023 Filed Mar 30, 2023 16:58 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | PurchaseCommon Stock | 31,250 | $1.60 | $50,000.00 |
DisclosureSEC source: 0001415889-23-005633 · form4-03302023_080339.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,259 Read SEC document |
| February 08, 2023 Filed Feb 8, 2023 22:51 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 3,269 | $15.75 | $51,500.81 |
DisclosureSEC source: 0001217234-23-000033 · wf-form4_167589664747342.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,468 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.715 to $15.930, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 02, 2023 Filed Feb 4, 2023 02:46 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 5,000 | $17.17 | $85,829.50 |
DisclosureSEC source: 0001217234-23-000027 · wf-form4_167547878932487.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,737 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.08 to $17.285, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 01, 2023 Filed Feb 4, 2023 02:46 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 5,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000027 · wf-form4_167547878932487.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,737 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was initially granted on February 3, 2021 for a two-year performance period over calendar years 2021 and 2022, which performance was assessed and finalized effective February 1, 2023. 50.00% of the reported securities vested on February 1, 2023 and 50% of the reported securities will vest on December 31, 2023, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:27 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 834 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-23-000012 · wf-form4_167330326198660.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,507 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:35 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 634 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000169 · wf-form4_166491895085119.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,673 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 01:49 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 4,585 | $25.57 | $117,253.12 |
DisclosureSEC source: 0001217234-22-000156 · wf-form4_166026898129861.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,039 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $25.80, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 01:49 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 15,415 | $24.38 | $375,890.15 |
DisclosureSEC source: 0001217234-22-000156 · wf-form4_166026898129861.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,624 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.20 to $25.165, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| August 10, 2022 Filed Aug 16, 2022 09:42 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | GrantCommon Stock | 12,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008658 · form4-08162022_060802.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,009 F1 · shares: Restricted Stock Units ("RSUs") that will fully vest on the earlier of the next annual meeting or one year from the date of the grant. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:36 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 487 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000138 · wf-form4_165713973683746.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,039 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:59 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock · Derivative | 7,606 | $0.00 Strike: $20.56 | $0.00 |
DisclosureSEC source: 0001217234-22-000113 · wf-form4_165584516954516.xml · derivative · entry 4 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,606 Underlying: Common Stock · 0 shares Expires 2032-06-16 F3 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 16, 2022 and the shares subject to the option shall vest monthly thereafter through June 16, 2023. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:59 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 4,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-22-000113 · wf-form4_165584516954516.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,552 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 16, 2023. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 21:03 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,198 | $0.00 Strike: $27.17 | $0.00 |
DisclosureSEC source: 0001217234-22-000078 · wf-form4_164927897682648.xml · derivative · entry 10 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,966 Underlying: Common Stock · 4,198 shares Expires 2029-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 25, 2020 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 21:03 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,627 | $0.00 Strike: $24.35 | $0.00 |
DisclosureSEC source: 0001217234-22-000078 · wf-form4_164927897682648.xml · derivative · entry 9 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,667 Underlying: Common Stock · 2,627 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 1/4th of the shares subject to the option vested on January 29, 2021 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 21:03 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001217234-22-000078 · wf-form4_164927897682648.xml · derivative · entry 8 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,942 Underlying: Common Stock · 3,125 shares Expires 2028-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 1/4th of the shares subject to the option vested on June 1, 2019 and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 21:03 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 2,018 | $39.35 | $79,416.98 |
DisclosureSEC source: 0001217234-22-000078 · wf-form4_164927897682648.xml · nonDerivative · entry 5 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,689 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.045 to $39.67, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 21:03 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 7,982 | $38.46 | $306,977.34 |
DisclosureSEC source: 0001217234-22-000078 · wf-form4_164927897682648.xml · nonDerivative · entry 4 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,707 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.04 to $38.83, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 21:03 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 4,198 | $27.17 | $114,059.66 |
DisclosureSEC source: 0001217234-22-000078 · wf-form4_164927897682648.xml · nonDerivative · entry 3 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 21:03 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 2,627 | $24.35 | $63,967.45 |
DisclosureSEC source: 0001217234-22-000078 · wf-form4_164927897682648.xml · nonDerivative · entry 2 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 21:03 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 3,125 | $12.24 | $38,250.00 |
DisclosureSEC source: 0001217234-22-000078 · wf-form4_164927897682648.xml · nonDerivative · entry 1 Maag Peter · CIK 0001613855 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.